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Abstract β-Adrenoceptors are important mediators of
smooth muscle relaxation in the urinary bladder, but the
concomitant presence of a muscarinic agonist, e.g., carba-
chol, can attenuate relaxation responses by reducing
potency and/or efficacy of β-adrenoceptor agonists such
as isoprenaline. Therefore, the present study was designed to
explore the subtypes and signalling pathways of muscarinic
receptors involved in the attenuation of isoprenaline-induced
isolated rat detrusor preparations using novel subtype-
selective receptor ligands. In radioligand binding studies, we
characterized BZI to be a M3-sparing muscarinic agonist,
providing selective M2 stimulation in rat bladder, and
THRX-182087 as a highly M2-selective antagonist. The
use of BZI and of THRX-182087 in the presence of
carbachol enabled experimental conditions with a selective
stimulation of only M2 or M3 receptors, respectively.
Confirming previous findings, carbachol attenuated
isoprenaline-induced detrusor relaxation. M2-selective stim-
ulation partly mimicked this attenuation, indicating that both
M2 and M3 receptors are involved. During M3-selective
stimulation, the attenuation of isoprenaline responses was
reduced by the phospholipase C inhibitor U 73,122 but not
by the protein kinase C inhibitor chelerythrine. We conclude
that both M2 and M3 receptors contribute to attenuation of β-
adrenoceptor-mediated relaxation of rat urinary bladder; the
signal transduction pathway involved in the M3 component
of this attenuation differs from that mediating direct
contractile effects of M3 receptors.
Keywords M2 muscarinic receptor.M3 muscarinic
receptor.THRX-182087.β-Adrenoceptor.Relaxation.
Urinary bladder
Introduction
Muscarinic receptors are the main mediator of physiological
contraction of the urinary bladder. While M2 and M3 subtypes
exist in an about 4:1 ratio in the bladder of humans and many
other mammals, direct contraction responses to exogenous
agonists or endogenous agonist as released by field stimula-
tion are mediated predominantly if not exclusively by the
minor fraction of M3 receptors (Hegde 2006). While it has
been questioned on theoretical grounds that subtype-selective
antagonists are sufficient to support this conclusion (Ehlert
2003), it should be noted that it is consistent with findings
from M2 and M3 receptor knockout mice (Matsui et al. 2002).
M3 receptors, including those in the urinary bladder, couple to
phospholipase C (PLC) stimulation, but the direct contractile
effect via M3 receptors occurs largely independent of PLC in
the bladder (Frazier et al. 2008). On the other hand, bladder
smooth muscle relaxation is mediated by β-adrenoceptors, in
humans and many species mostly their β3 subtype (Michel
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DOI 10.1007/s00210-011-0689-8and Vrydag 2006). While β-adrenoceptors, including those in
the bladder, couple to stimulation of an adenylyl cyclase,
bladder relaxation by β-adrenergic agonists occurs largely
independent of adenylyl cyclase stimulation (Frazier et al.
2008). Thus, bladder smooth muscle tone is under a dual
control of M3 muscarinic receptors and β-adrenoceptors. This
i ss i m i l a rt os m o o t hm u s c l et o n er e g u l a t i o ni nm a n yo t h e r
tissues, e.g., the airways, except relaxation responses in most
cases outside the bladder are mediated by the β2 subtype
(Michel and Parra 2008).
The physiological control of bladder function involves
activation of β-adrenoceptors by neuronally released nor-
adrenaline during the storage phase of the micturition cycle,
whereas neuronally released acetylcholine acting on M3
receptors mediates detrusor contraction during the voiding
phase (Andersson et al. 2009). However, under pathophys-
iological conditions nonneuronal acetylcholine release from
the urothelium may also play a role and can be present not
only during the voiding but also the storage phase
(Andersson 2011). The concomitant exposure of the detrusor
to noradrenaline and acetylcholine during the storage phase
may have important implications for bladder smooth muscle
function. Thus, it has been shown that the potency and
efficacy of a muscarinic agonist to elicit detrusor contraction
is attenuated in the presence of a β-adrenoceptor agonist
(Yamanishi et al. 2002). Perhaps even more important,
muscarinic agonists can also attenuate the relaxing effects
of β-adrenoceptor stimulation in the bladder (Ehlert et al.
2007; Longhurst and Levendusky 1999; Michel and Sand
2009), airways (Matsui et al. 2003;N a l i n ee ta l .2007;S a r r i a
et al. 2002), and ileum (Matsui et al. 2003). Such attenuation
has been shown across multiple species, i.e., rat (Longhurst
and Levendusky 1999; Michel and Sand 2009), mouse
(Ehlert et al. 2007;M a t s u ie ta l .2003), and humans (Naline
et al. 2007;S a r r i ae ta l .2002), indicating that it is a general
principle in the regulation of smooth muscle tone upon
concomitant exposure to muscarinic and β-adrenoceptor
agonists. While all studies agree on the existence of
attenuation of β-adrenoceptor-mediated relaxation by mus-
carinic agonists, reduced potency and/or efficacy have been
reported to underlie such attenuation. Of note, the degree of
attenuation of β-adrenoceptor-mediated relaxation by mus-
carinic agonists exceeds that by other contractile stimuli in
all cases where this has been studied, e.g., that by KCl,
bradykinin, or serotonin in the bladder (Michel and Sand
2009) or that of histamine in the airways (Naline et al. 2007;
Roffel et al. 1995). At least in rat bladder, this differential
degree of attenuation cannot be explained by a comparison
between weak and strong contractile agonists, indicating that
it may involve a specific property of muscarinic receptors
rather than purely reflecting functional antagonism.
The interaction between muscarinic receptors and β-
adrenoceptors may also shed light on the physiological role
of the numerous M2 receptors in bladder and airways. Thus,
M2 receptor knockout mice exhibited a mitigated attenua-
tion of relaxation responses to isoprenaline (Ehlert et al.
2007; Matsui et al. 2003) and receptor-independent eleva-
tion of cellular cAMP content such by the adenylyl cyclase
activator forskolin (Pak et al. 2010). AsM2 receptors largely
signal via pertussis toxin-sensitive G proteins (Caulfield and
Birdsall 1998), further support for a role of M2 receptors in
the attenuation response comes from studies in which
pertussis toxin treatment enhanced the relaxant effects of
forskolin on oxotremorine-M-mediated contractions in the
ileum and trachea (Ostrom and Ehlert 1998, 1999). In a
similar vein, it has been reported that under conditions of
preferential alkylation of M3 receptors, the ability of a
muscarinic agonist to reverse isoprenaline-induced relaxation
is largely maintained (Ehlert et al. 2005; Hegde et al. 1997).
Facing a lack of highly subtype-selective muscarinic
antagonists, such alkylation protocols have been employed
by several investigators to achieve reasonable subtype
selectivity. While this has been successful in some cases
under very specific conditions (Griffin et al. 2009), other
alkylation protocols have proven to be poorly selective
(Braverman and Ruggieri 1999). Moreover, in some cases,
M3 responses have also been pertussis toxin sensitive
(Offermanns et al. 1994), making pertussis toxin an
unreliable witness of M2 involvement. While the knockout
mice circumvent selectivity problems, they are prone to other
complications such as compensatory regulation of other
receptors or signal transduction pathways.
Recently, an agonist with considerable selectivity for M2
over M3 receptors became available, but this compound
exhibits a lower degree of selectivity, if any, over other
subtypes; in the bladder, where muscarinic receptor subtypes
other than M2 and M3 are largely absent, this compound
produces selective M2 stimulation (Jasper et al. 2002;
Schneider et al. 2005; Yamakawa et al. 2001a). Lacking a
better term, we refer to this compound as “M3 sparing” in the
present manuscript. Moreover, we have recently discovered
an M2 receptor antagonist with unprecedented selectivity for
this subtype, which we report here for the first time (Fig. 1).
These two tools have enabled us to explore the role of M2
and M3 receptors in the attenuation of isoprenaline-induced
bladder relaxation. Moreover, we have used this approach to
characterize the role of PLC and protein kinase C (PKC)
activation in the attenuation response.
Methods
Radioligand binding experiments
Radioligand binding assays were conducted with 1 nM [
3H]
N-methyl scopolamine (GE Healthcare, Piscataway, NJ,
556 Naunyn-Schmiedeberg's Arch Pharmacol (2011) 384:555–563USA) in a buffer consisting of 10 mM HEPES, 100 mM
NaCl, 10 mM MgCl2, and 0.025% bovine serum albumin,
pH 7.4 at 37°C. Nonspecific binding was defined in the
presence of 10 μM atropine. Membrane fractions from
CHO-K1 cells expressing human recombinant M1,M 2,M 3,
M4,o rM 5 muscarinic receptors were incubated with
radioligand and unlabelled drugs for 1 h at 37°C in a
volume of 100 μl. Receptor expression levels (Bmax)
measured by saturation binding were determined to be
2.7, 2.5, 2.4, 2.0, and 3.2 pmol/mg protein for human
recombinant M1,M 2,M 3,M 4,o rM 5 muscarinic receptors,
respectively. After separation by vacuum filtration ontoGF/B
filter plates presoaked with 0.3% polyethyleneimine, the
quantity of membrane-bound radioligand was measured by
scintillation counting.
Organ bath experiments
Tissue preparation Adult male Wistar rats weighing 300±
22 g were purchased from Charles River (Maastricht, The
Netherlands). Animals were anesthetized using pentobarbi-
tal (75 mg/kg, i.p.) and sacrificed by decapitation. The
bladders were harvested, and adipose and soft connective
tissues were removed. After removal of the dome and the
trigonum, the middle parts of the cleaned bladders (weight of
96±15 mg) were cut transversally in four equal strips. The
strips had a length of 19.9±3.6 mm and a weight of 9.5±
2.7 mg (n=76). All experimental procedures were in line
with European Union guidelines for the use of laboratory
animals and approved by the Animal Care Committee of
Academisch Medisch Centrum.
Relaxation experiments Experiments were performed as
previously described (Frazier et al. 2011) with minor
modifications. Briefly, the bladder strips were mounted
under a resting tension of 10 mN in organ baths containing
7 ml of Krebs–Henseleit buffer of the following composi-
tion: 118.5 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4,
0.025 mM Na4EDTA, 2.5 mM CaCl2, 1.2 mM KH2PO4,
25 mM NaHCO3, and 5.6 mM glucose at a temperature of
37°C, yielding a total potassium concentration of 5.9 mM.
The organ baths were continually gassed 95% O2/5% CO2
to maintain a pH of 7.4. The bladder strips were
equilibrated for 120 min, during which the buffer solution
was refreshed every 15 min until a steady contractile state
had been reached. Following the equilibration, the tissues
were challenged with 50 mM KCl for 6 min (maintaining
isoosmolarity by reducing NaCl concentration from 116.8
to 68.5 mM). After the first challenge, we equilibrated the
strips again at passive tension of 10 mN for 90 min and
challenged the strips again with 50 mM KCl for 6 min.
After 60 min equilibration at 10 mN after the second KCl
challenge, we added vehicle or substance of interest. Strips
with a KCl response of <20 mN were excluded. Carbachol
was used at a concentration of 1 μM, BZI and THRX at
100 nM. The enzyme inhibitors U 73,122 (10 μM) and
chelerythrine (1 μM) were added 5 min prior to the
administration of THRX. Ten minutes later carbachol
(1 μM) was added, which was given an incubation time
of 15 min to reach steady contractile stadium. Thereafter,
cumulative concentration–response curves were generated
for the β-adrenoceptor agonist isoprenaline. As
isoprenaline-induced rat bladder relaxation can exhibit
desensitization (Vrydag and Michel 2009), only one
isoprenaline concentration–response curve was constructed
per bladder strip; however, conditions being compared were
always tested in parallel using strips from the same animal,
and those paired comparisons were the basis of our
statistical analysis (see below).
Chemicals
The M3-sparing agonist BZI [also known as THRX-
199874, 4-(2-oxo-2,3-dihydro-benzimidazol-1-yl)-1,4′-bipi-
peridinyl-1′-carboxylic acid ethyl ester] was synthesized at
Theravance as described (Yamakawa et al. 2001b). The M2-
selective antagonist THRX-182087 [N-(3-{(R)-1-[1-(1H-
imidazole-4-carbonyl)-piperidin-4-ylmethyl]-piperidin-2-
ylmethyl}-phenyl)-4-methoxy-benzamide] was synthesized
in house as follows: Preparation of THRX-182087 was
initiated from the condensation of 4-methoxyl benzoyl
chloride and 3-bromo aniline. Metal halogen exchange with
n-butyllithium in the presence of triethylchlorosilane and
addition to (R)-2-formyl-1-Cbz-piperidine, followed by
decarboxylation with palladium on carbon and potassium
formate. Reductive alkylation with 4-formyl-1-Cbz-piperi-
dine and Cbz removal with palladium on carbon, followed
Fig. 1 Structures of THRX-
199874 (BZI) and
THRX-182087
Naunyn-Schmiedeberg's Arch Pharmacol (2011) 384:555–563 557by acylation with 1H-imidazole-4-carbonyl chloride
provided THRX-182087 (for detailed synthetic route see
Stangeland et al., manuscript in preparation). U 73,122 [1-
(6-[([17ß]-3-methoxyestra-1,3,5[10]-trien-17-yl)-amino]
hexyl)-1H-pyrrole-2,5-dione] was obtained from Sigma-
Aldrich (Zwijndrecht, The Netherlands) and chelerythrine
HCl from Calbiochem (via VWR, Amsterdam, The
Netherlands).
Data analysis
Bound radioactivity in counts-per-minute data was normal-
ized to percent specific binding and analyzed using a four-
parameter logistic equation in Prism 3.0 (GraphPad
Software, San Diego, CA, USA). Because Hill coefficients
did not significantly differ from unity, IC50s were deter-
mined with slopes fixed to 1. Inhibition binding constants
(KI) for test compounds were calculated from the IC50
values using the Cheng and Prusoff correction (Cheng and
Prusoff 1973) and reported as the mean negative logarithm
of the inhibition binding constants (pKI) ± SEM.
Nonlinear regression was used to fit sigmoidal curves
to the isoprenaline concentration–response curves to
determine agonist potency (pEC50) and maximum effects
(Emax) using Prism 5.0. The force of contraction immedi-
ately prior to addition of the first isoprenaline concentra-
tion within a given experiment was defined as 0%
relaxation, and a force of contraction of 0 mN was defined
as 100% relaxation.
All data are expressed as mean±SEM of n experiments.
Statistical significance of inhibitor effects on the Emax or
pEC50 of isoprenaline was assessed by paired two-tailed t
tests as compared to the indicated control condition, with
treated and control conditions being measured in paired
strips prepared from the same bladder. All statistical
analyses were calculated using the Prism program, and a
p<0.05 was considered statistically significant.
Results
The affinities of BZI and THRX-182087 for human
recombinant M1,M 2,M 3,M 4,a n dM 5 muscarinicreceptors
as determined in competition radioligand binding experi-
m e n t sa r es h o w ni nT a b l e1, most notably demonstrating
a >100-fold selectivity for M2 over M3 receptors for both
compounds.
Five series of functional experiments were performed. In
the first series, we reinvestigated the role of muscarinic
receptor stimulation vs. receptor-independent bladder con-
traction, induced by KCl, for isoprenaline-induced relaxa-
tion. Carbachol and KCl caused a comparable starting
tension (Table 2). The maximum relaxation by isoprenaline
was significantly smaller in carbachol- than KCl-
precontracted strips, whereas the potency of isoprenaline
Table 1 Affinity estimates of BZI and THRX-182087 at human
muscarinic receptor subtypes as determined in competition radioligand
binding studies
BZI THRX-182087
M1 7.27±0.04 6.82±0.02
M2 8.59±0.05 9.06±0.02
M3 <5 6.61±0.02
M4 8.01±0.05 7.34±0.02
M5 6.11±0.05 5.46±0.02
Data are means±SEM of 19–27 experiments and shown as pKI values
Table 2 Starting tension of
relaxation experiments in the
absence and presence of musca-
rinic agonists and antagonists
and/or signal transduction
inhibitors
Data are means±SEM of the
indicated number of experi-
ments and shown in millinew-
tons per milligram strip weight
*p<0.05 vs. test condition (KCl,
carbachol, or passive tension) in
a paired, two-tailed t test
Series 1: KCl vs. mixed muscarinic stimulation
KCl, 50 mM 2.86±0.22 n=8
Carbachol, 1 μM 2.46±0.12 n=8
Series 2: passive tension vs. M2 stimulation
Passive 0.95±0.15 n=6
BZI, 100 nM 1.08±0.10 n=6
Series 3: mixed vs. M3 stimulation
Carbachol, 1 μM 2.60±0.13 n=6
Carbachol, 1 μM + THRX-182087, 100 nM 2.14±0.22 n=6
Series 4: M3 stimulation in absence and presence of phospholipase C inhibitor
Carbachol, 1 μM + THRX-182087, 100 nM 2.90±0.21 n=6
Carbachol, 1 μM + THRX-182087, 100 nM + U 73,122, 10 μM 2.33±0.12* n=6
Series 5: M3 stimulation in absence and presence of protein kinase C inhibitor
Carbachol, 1 μM + THRX-182087, 100 nM 2.89±0.51 n=6
Carbachol, 1 μM + THRX-182087, 100 nM + chelerythrine, 1 μM 2.90±0.22 n=6
558 Naunyn-Schmiedeberg's Arch Pharmacol (2011) 384:555–563did not differ significantly between the two conditions
(Fig. 2).
The second series of experiments explored whether
selective M2 receptor stimulation mimics the effect of
carbachol. Based upon previous data that BZI alone causes
little bladder contraction (Schneider et al. 2005), we
compared BZI with passive tension and confirmed the lack
of effect of BZI on detrusor tone (Table 2). While BZI did
not affect maximum isoprenaline-induced relaxation, it
significantly reduced its potency (Fig. 3).
The third series addressed the reverse question, i.e.,
whether selective M3 receptor stimulation (carbachol in
presence of THRX-182087) mimics the carbachol effect.
Both conditions caused comparable starting tension (Table 2).
The potency and efficacy of isoprenaline were significantly
greater upon M3 selective as compared to general muscarinic
receptor stimulation, confirming a contribution of M2
receptors to the attenuation of the isoprenaline response
(Fig. 4). However, the enhancement of isoprenaline
responses by M2 blockade (Fig. 4) was quantitatively less
than the attenuation by carbachol (Fig. 2), indicating that
both subtypes contribute to the attenuation of isoprenaline
responses by carbachol.
The fourth and fifth series of experiments explored
whether PLC and/or PKC contribute to the attenuation of
isoprenaline responses by M3-selective stimulation. In the
presence of the PLC inhibitor U 73,122 starting tension was
significantly smaller than with M3-selective stimulation
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Fig. 2 Comparison of isoprenaline-induced relaxation against
tension induced by 50 mM KCl and 1 μM carbachol. Upper
panel data are means±SEM (n=6). Middle and lower panel bars
showing Emax and pEC50 asderivedfromthecurvesinthe upper panel
indicate means±SEM, whereas filled circles represent individual experi-
ments. *p<0.05 vs. KCl in a paired t test
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Fig. 3 Comparison of passive tension and M2-selective muscarinic
stimulation by 100 nM BZI on isoprenaline-induced relaxation. Upper
panel data are means±SEM (n=6). Middle and lower panel bars
showing Emax and pEC50 as derived from the curves in the upper
panel indicate means±SEM, whereas filled circles represent individual
experiments. *p<0.05 vs. passive tension in a paired t test
Naunyn-Schmiedeberg's Arch Pharmacol (2011) 384:555–563 559alone (Table 2). Potency and efficacy of isoprenaline were
significantly greater in the presence of U 73,122 (Fig. 5). In
contrast, the PKC inhibitor chelerythrine affected neither
starting tension (Table 2) nor potency or efficacy of
isoprenaline-induced relaxation (Fig. 6).
Discussion
Our study introduces a novel highly M2-selective antago-
nist (THRX-182087) and uses it together with the M3-
sparing agonist BZI to explore the muscarinic receptor
subtypes involved in the attenuation of isoprenaline effects
in rat urinary bladder as well as the signalling pathways
mediating such attenuation. According to our competition
binding data, THRX-182087 is 281-fold selective for M2
over M3 receptors. Selectivity over other muscarinic
receptors is 50–4,000-fold. This compares favorably to the
limited M2 selectivity of other compounds which have been
used in this field such as methoctramine which is only 30-
fold selective (Hegde et al. 1997). While the selectivity of
THRX-182087 over M4 receptors is less pronounced, these
receptors are of little importance in the regulation of
bladder smooth muscle tone (Hegde 2006). Hence, for
practical purposes, THRX-182087 is a highly selective M2
antagonist in our experimental setting. The THRX-182087
Emax
carbachol + THRX
0
20
40
60
80
*
%
 
r
e
l
a
x
a
t
i
o
n
pEC50
carbachol + THRX
6
7
8
9
*
-
l
o
g
 
M
-8 -6 -4
0
20
40
60
80
Carbachol
THRX
[Isoprenaline] (logM)
r
e
l
a
x
a
t
i
o
n
,
 
%
Fig. 4 Comparison of mixed (1 μM carbachol) vs. M3-selective
muscarinic stimulation (1 μM carbachol + 100 nM THRX-182087)
on isoprenaline-induced relaxation. Upper panel data are means±SEM
(n=6). Middle and lower panel bars showing Emax and pEC50 as
derived from the curves in the upper panel indicate means±SEM,
whereas filled circles represent individual experiments. *p<0.05 vs.
carbachol alone in a paired t test
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Fig. 5 Effect of the phospholipase C inhibitor U 73,122 (10 μM) on
isoprenaline-induced relaxation during M3-selective stimulation (1 μM
carbachol + 100 nM THRX). Upper panel data are means±SEM (n=6).
Middle and lower panel bars showing Emax and pEC50 as derived from
the curves in the upper panel indicate means±SEM, whereas filled
circles represent individual experiments. *p<0.05 vs. data in absence of
signalling inhibitor in a paired t test
560 Naunyn-Schmiedeberg's Arch Pharmacol (2011) 384:555–563concentration of 100 nM used in our studies produces an
almost complete occupancy of M2 receptors, and accord-
ingly the combination of carbachol with THRX-182087
provides selective M3 agonism.
BZI has been introduced as an M3-sparing agonist
(Jasper et al. 2002; Yamakawa et al. 2001a), and our
binding data show a more than 3,000-fold selectivity for M2
over M3 receptors. Selectivity over other muscarinic
receptors is 3–390-fold. Accordingly, BZI provides selec-
tive stimulation of M2 receptors in bladder smooth muscle,
where only M2 and M3 receptors are functionally relevant
(Hegde 2006). The combined use of THRX-182087 and
BZI has enabled us to explore the relative roles of M2 and
M3 receptors in the attenuation of isoprenaline-induced
relaxation.
Our data on starting tension demonstrate that inhibition
of the M2 receptors did not attenuate carbachol responses,
whereas selective activation of M2 receptors did not induce
contraction as also observed in previous studies (Schneider
et al. 2005). These data confirm a large body of evidence
that despite the much larger presence of M2 receptors in the
urinary bladder, direct contractile responses are mediated
predominantly if not exclusively by the M3 receptor (Hegde
2006).
Studies in multiple tissues and species had demonstrated
thatmuscarinicreceptors canattenuate relaxationresponses to
the β-adrenoceptor agonist isoprenaline (see “Introduction”
section), and this is confirmed in the present data. While
such attenuation was found very consistently, those previous
studies had been inconsistent with regard to the question
whether such attenuation affects the potency and/or efficacy
of isoprenaline, and our data also are not fully consistent in
this regard.
Studies based on knockout mice had indicated that the
M2 subtype, which contributes little to direct detrusor
contraction, plays a role in the attenuation of the relaxation
response (Ehlert et al. 2005; Matsui et al. 2003; Pak et al.
2010). Using the complementary approach of selective
pharmacological stimulation by BZI, we confirm a role of
M2 receptors in the attenuation of relaxation. Our finding
that selective inhibition of M2 receptors by THRX-182087
in the presence of carbachol enhances relaxation by
isoprenaline further corroborates this idea. However, it
should be noted that neither the effect of BZI nor that of
THRX-182087 can fully explain the attenuation obtained
by mixed muscarinic stimulation using carbachol alone,
suggesting that the attenuation response may also contain
an M3 component.
Stimulation of the PLC/PKC pathway is a prototypical
signalling response of M3 receptors (Caulfield and Birdsall
1998; Ehlert et al. 1997) which also was detected in the
bladder as being mediated predominantly if not exclusively
via M3 receptors (Kories et al. 2003; Nelson et al. 2004).
Nevertheless, M3 receptor-mediated bladder contraction has
been shown to be insensitive to inhibition of PLC or PKC
in rats, mice, and humans (Frazieretal.2008). In the present
study, we have used the PLC inhibitor U 73,122 in a
concentration where it fully suppresses inositol phosphate
formation in the bladder but does not affect rat or human
bladder contraction (Schneider et al. 2004a, b). Interestingly,
U 73,122 significantly enhanced isoprenaline-induced relax-
ation in the presence of M3-selective stimulation. Thus, PLC
may be involved in the M3 component of attenuation of
relaxation but not in direct bladder contraction mediated by
the same receptor subtype. According to our data, PKC is
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Fig. 6 Effect of the the protein kinase C inhibitor chelerythrine
(1 μM) on isoprenaline-induced relaxation during M3-selective
stimulation (1 μM carbachol + 100 nM THRX-182087). Upper panel
data are means±SEM (n=6). Middle and lower panel bars showing
Emax and pEC50 as derived from the curves in the upper panel indicate
means±SEM, whereas filled circles represent individual experiments.
Data in the absence and presence of the signalling inhibitor were not
significantly different in a paired t test (p>0.05)
Naunyn-Schmiedeberg's Arch Pharmacol (2011) 384:555–563 561not involved in either response, indicating that the involve-
ment of PLC in the attenuation of relaxation occurs via a
PKC-independent pathway.
In conclusion, we have introduced a novel antagonist
with very high selectivity for M2 over M3 receptors,
THRX-182087. Using this compound as well as the M3-
sparing agonist BZI, we confirm a role for M2 receptors in
the attenuation of isoprenaline-induced bladder relaxation,
which previously was mainly supported by genetic evi-
dence, by a pharmacological approach. Our data also
suggest involvement of M3 receptors in this attenuation.
Thus, muscarinic receptors cause direct contraction and
inhibition of relaxation in the bladder, but the two responses
involve different subtypes and, at least for M3 receptors,
different signalling pathways. This interaction may become
clinically relevant under pathophysiological conditions
when acetylcholine is being released in the bladder during
the storage phase of the micturition cycle.
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